

ESVAC stakeholders Meeting

2nd March 2016



Introduction

- We support the excellent work done by ESVAC on the collection of use data.
- We have been engaged since the start of the project and have collaborated reporting sales data.
- We strongly support transparency at the use phase.
- As such we support the move to collect species data



Collection of data by species

- We agree that it will take a number of years for all MS to implement systems to collect reliable species data at the farm level.
- Development of standard guidance and methodology is beneficial.
- Encourage MS to work together where possible
 - Increase compatibility of data
 - Decrease costs of system development.
- IDMP
 - Needs to be kept proportionate to scale and needs of the industry.



Feasibility of Stratification

- Data reported by MAH will be accurate only for total sales, not on a species level – no data
 - Species split, raw numbers from Eurostat but disease frequencies?
 - Destination Member State
- Wholesalers report most of the ESVAC data, not MAH
 - “Sixteen of the countries obtained the data from wholesalers, six from marketing authorisation holders, two from both wholesalers and marketing authorisation holders and two from pharmacies”(ESVAC 2015)
- By definition, it is very difficult to report off label data
- Data is best gathered as close to the point of use as feasible.

Feasibility of Stratification

- Possible ways forward:
 - Initially limit Species data to those countries or species where it is already collected.
 - Add additional countries as the data becomes available.
 - Data from MAH/Wholesaler confirmed by pilot farm level data collection (e.g. France)